摘要
Monoclonal gammopathy of renal significance(MGRS)is a pathological state which presents with a spectrum of renal lesions.MGRS is characterized by pathogenic monoclonal immunoglobulins or light chains produced by a premalignant plasma cell or B cell clone.In view of inadequate understanding in the past,the low detection rate of MGRS often results in poor outcomes and reduces quality of life of patients.Thus,MGRS stands for a group of clinical refractory renal diseases.To date,no standard treatment strategy for MGRS is available.Current consensus suggests a clone-directed approach that aims to eradicate the offending clone,but its long-term prognosis is not clear.In this article,we discuss the diagnostic methods,highlight treatment advances,and introduce integrated Chinese and Western medicine in the management of MGRS.
